
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PeerJ</journal-id><journal-id journal-id-type="iso-abbrev">PeerJ</journal-id><journal-id journal-id-type="pmc">PeerJ</journal-id><journal-id journal-id-type="publisher-id">PeerJ</journal-id><journal-title-group><journal-title>PeerJ</journal-title></journal-title-group><issn pub-type="epub">2167-8359</issn><publisher><publisher-name>PeerJ Inc.</publisher-name><publisher-loc>San Diego, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30867996</article-id><article-id pub-id-type="pmc">6410685</article-id><article-id pub-id-type="publisher-id">6583</article-id><article-id pub-id-type="doi">10.7717/peerj.6583</article-id><article-categories><subj-group subj-group-type="heading"><subject>Virology</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology</subject></subj-group><subj-group subj-group-type="heading"><subject>Gastroenterology and Hepatology</subject></subj-group><subj-group subj-group-type="heading"><subject>Infectious Diseases</subject></subj-group></article-categories><title-group><article-title>Patterns of hepatitis B virus <italic>S</italic> gene escape mutants and reverse transcriptase mutations among genotype D isolates in Jordan</article-title></title-group><contrib-group><contrib id="author-1" contrib-type="author" equal-contrib="yes"><name><surname>Ababneh</surname><given-names>Nidaa A.</given-names></name><xref ref-type="aff" rid="aff-1">1</xref></contrib><contrib id="author-2" contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0165-9670</contrib-id><name><surname>Sallam</surname><given-names>Malik</given-names></name><xref ref-type="aff" rid="aff-2">2</xref><xref ref-type="aff" rid="aff-3">3</xref><xref ref-type="aff" rid="aff-4">4</xref><email>malik.sallam@ju.edu.jo</email></contrib><contrib id="author-3" contrib-type="author"><name><surname>Kaddomi</surname><given-names>Doaa</given-names></name><xref ref-type="aff" rid="aff-5">5</xref></contrib><contrib id="author-4" contrib-type="author"><name><surname>Attili</surname><given-names>Abdelrahman M.</given-names></name><xref ref-type="aff" rid="aff-6">6</xref></contrib><contrib id="author-5" contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8999-8334</contrib-id><name><surname>Bsisu</surname><given-names>Isam</given-names></name><xref ref-type="aff" rid="aff-6">6</xref></contrib><contrib id="author-6" contrib-type="author"><name><surname>Khamees</surname><given-names>Nadia</given-names></name><xref ref-type="aff" rid="aff-5">5</xref></contrib><contrib id="author-7" contrib-type="author"><name><surname>Khatib</surname><given-names>Amer</given-names></name><xref ref-type="aff" rid="aff-5">5</xref></contrib><contrib id="author-8" contrib-type="author" corresp="yes"><name><surname>Mahafzah</surname><given-names>Azmi</given-names></name><xref ref-type="aff" rid="aff-2">2</xref><xref ref-type="aff" rid="aff-3">3</xref><email>mahafzaa@ju.edu.jo</email></contrib><aff id="aff-1"><label>1</label><institution>Cell Therapy Center (CTC), University of Jordan</institution>, <addr-line>Amman</addr-line>, <country>Jordan</country></aff><aff id="aff-2"><label>2</label><institution>Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, University of Jordan</institution>, <addr-line>Amman</addr-line>, <country>Jordan</country></aff><aff id="aff-3"><label>3</label><institution>Department of Clinical Laboratories and Forensic Medicine, Jordan University Hospital</institution>, <addr-line>Amman</addr-line>, <country>Jordan</country></aff><aff id="aff-4"><label>4</label><institution>Department of Translational Medicine, Faculty of Medicine, Lund University</institution>, <addr-line>Malm&#x000f6;</addr-line>, <country>Sweden</country></aff><aff id="aff-5"><label>5</label><institution>Gastroenterology and Liver Division, Department of Internal Medicine, Jordan University Hospital</institution>, <addr-line>Amman</addr-line>, <country>Jordan</country></aff><aff id="aff-6"><label>6</label><institution>School of Medicine, University of Jordan</institution>, <addr-line>Amman</addr-line>, <country>Jordan</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>B&#x000f6;ttcher</surname><given-names>Bettina</given-names></name></contrib></contrib-group><pub-date pub-type="epub" date-type="pub" iso-8601-date="2019-03-08"><day>8</day><month>3</month><year iso-8601-date="2019">2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>7</volume><elocation-id>e6583</elocation-id><history><date date-type="received" iso-8601-date="2018-10-10"><day>10</day><month>10</month><year iso-8601-date="2018">2018</year></date><date date-type="accepted" iso-8601-date="2019-02-08"><day>8</day><month>2</month><year iso-8601-date="2019">2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 Ababneh et al.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Ababneh et al.</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.</license-p></license></permissions><self-uri xlink:href="https://peerj.com/articles/6583"/><abstract><sec><title>Background</title><p>Hepatitis B virus (HBV) is an important infectious cause of morbidity and mortality in Jordan. HBV genotype D is the most prevalent in the country. Virus escape mutants in the HBV <italic>S</italic> region is an important public health problem halting preventive efforts. The aim of the current study was to investigate patterns of HBV escape and resistance mutations and to assess domestic transmission of the virus.</p></sec><sec><title>Methods</title><p>Patients infected with HBV were recruited at Jordan University Hospital (<italic>n</italic> = 56) and were diagnosed during (1984&#x02013;2012). A total of 37 partial HBV <italic>S</italic> sequences were generated using Sanger&#x02019;s method. Mutation analysis was done using the HIV grade HBV drug resistance interpretation online tool and Geno2pheno (HBV) online tools. Domestic transmission of HBV was assessed using maximum likelihood phylogenetic inference with similar GenBank sequences.</p></sec><sec><title>Results</title><p>Genotyping revealed an exclusive presence of sub-genotype D1. Typical HBV escape mutants were identified in seven patients. These mutations included: L109R, Q129R, M133L, S143L and D144E with overall prevalence of 18.9% (95% CI [9.5&#x02013;34.2]). Reverse transcriptase (RT) sequence analysis showed mutations in three patients with overall prevalence of 8.1% (95% CI [2.8&#x02013;21.3]). RT mutations included: V173L, S202I, L180M, M204V and T184A. Transmission cluster analysis revealed a relatively high proportion of infections taking place as a result of domestic spread (29.7%).</p></sec><sec><title>Conclusions</title><p>Based on our findings, RT mutation analysis appears to be of high value before the initiation of therapy in patients with chronic HBV infection in Jordan. Phylogenetic analyses revealed a considerable proportion of local spread in the country which should be considered in the preventive infection control efforts.</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Hepatitis B</kwd><kwd>HBV</kwd><kwd>Mutation</kwd><kwd>Phylogeny</kwd><kwd>Epidemiology</kwd></kwd-group><funding-group><award-group id="fund-1"><funding-source>Deanship of Academic Research, the University of Jordan</funding-source></award-group><funding-statement>This work was supported by funding from the Deanship of Academic Research at the University of Jordan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The infection by hepatitis B virus (HBV) is considered a major cause of hepatic-related morbidity and mortality globally with an estimated 257 million people living with chronic infection and approximately 887,000 HBV-related deaths by the end of 2015 (<xref rid="ref-21" ref-type="bibr">World Health Organization, 2017</xref>).</p><p>The distinguished features of HBV among other human viruses can be summarized as follows: HBV genome is a partially double-stranded circular DNA of extremely small size (about 3,300 bases) with overlapping open reading frames. In addition, HBV replication cycle is peculiar in respect of an intermediate step involving an error-prone reverse transcriptase (RT), and is manifested in a faster evolution compared to other DNA viruses (<xref rid="ref-19" ref-type="bibr">Fares &#x00026; Holmes, 2002</xref>; <xref rid="ref-61" ref-type="bibr">Zhou &#x00026; Holmes, 2007</xref>). The high evolutionary rate of HBV have resulted in its diversification in the human population with emergence of several genotypes (A&#x02013;J), based on inter-genotype sequence variation of more than 8% (<xref rid="ref-41" ref-type="bibr">Okamoto et al., 1988</xref>; <xref rid="ref-47" ref-type="bibr">Schaefer, 2007</xref>; <xref rid="ref-51" ref-type="bibr">Stuyver et al., 2000</xref>; <xref rid="ref-52" ref-type="bibr">Tatematsu et al., 2009</xref>; <xref rid="ref-57" ref-type="bibr">Yu et al., 2010</xref>). The HBV genotypes are further split into subgenotypes designated by numbers based on intra-genotype sequence variation of 4&#x02013;8% (<xref rid="ref-39" ref-type="bibr">Norder et al., 2004</xref>). Moreover, recombination events have expanded the genetic diversity of HBV with evidence of substantial influence on shaping the evolutionary history of the virus (<xref rid="ref-50" ref-type="bibr">Simmonds &#x00026; Midgley, 2005</xref>).</p><p>The unique features of HBV genome, particularly for the wide spread of overlapping open reading frames, have implications on treatment and prevention of the virus spread (<xref rid="ref-29" ref-type="bibr">Liang, 2009</xref>). This is particularly evident as follows: mutations arising in the RT region as a result of selective pressure by antiviral drugs can end up in the emergence of virus escape mutants in the adjacent <italic>S</italic> region with subsequent lack of response to HBV vaccine (<xref rid="ref-12" ref-type="bibr">Caligiuri et al., 2016</xref>; <xref rid="ref-16" ref-type="bibr">Croagh, Desmond &#x00026; Bell, 2015</xref>). Among the most commonly described mutations in the RT region are mapped at the codons I169, L180, A181, T184, S202, M204, N236 and M250 (<xref rid="ref-33" ref-type="bibr">Locarnini &#x00026; Yuen, 2010</xref>). These mutations can arise due to inadequate HBV therapy particularly with drugs that have low genetic barrier for resistance (lamivudine; 3TC) with some mutations having enhanced replication and competence effect on the virus (<xref rid="ref-11" ref-type="bibr">Bock et al., 2002</xref>; <xref rid="ref-33" ref-type="bibr">Locarnini &#x00026; Yuen, 2010</xref>; <xref rid="ref-34" ref-type="bibr">Luber, 2005</xref>).</p><p>It is now confirmed by several reports (<xref rid="ref-32" ref-type="bibr">Lin et al., 2005</xref>; <xref rid="ref-35" ref-type="bibr">Luongo et al., 2015</xref>; <xref rid="ref-56" ref-type="bibr">Ye, Shang &#x00026; Li, 2015</xref>), that transmission of HBV can occur despite successful vaccination as evidenced by the persistence of hepatitis B surface antibody (anti-HBs) in the patients. In addition, mutant viruses may evade serologic detection by the currently used enzyme immunoassays (<xref rid="ref-49" ref-type="bibr">Sheldon &#x00026; Soriano, 2008</xref>; <xref rid="ref-53" ref-type="bibr">Teo &#x00026; Locarnini, 2010</xref>). This can end up in the occurrence of occult hepatitis B infection (<xref rid="ref-42" ref-type="bibr">Purdy, 2007</xref>). On the other hand, a few studies indicated that the public health concerns of escape mutants might not be as previously feared (<xref rid="ref-28" ref-type="bibr">Leong, Lin &#x00026; Nguyen, 2016</xref>). The prototypic and most stable vaccine-escape mutant is G145R (<xref rid="ref-26" ref-type="bibr">Hsu et al., 2004</xref>; <xref rid="ref-42" ref-type="bibr">Purdy, 2007</xref>). Among other commonly detected vaccine-escape mutants are: P120Q, Q129H, F134Y/L, S143L and D144A/E (<xref rid="ref-14" ref-type="bibr">Coppola et al., 2015</xref>).</p><p>In Jordan, the sero-prevalence of chronic HBV was estimated to range between 1.4% and 3.5% indicating a low-intermediate endemicity of the virus (<xref rid="ref-10" ref-type="bibr">Batayneh &#x00026; Bdour, 2002</xref>; <xref rid="ref-23" ref-type="bibr">Hamoudi, Ghazzawi &#x00026; Hamoudi, 2016</xref>; <xref rid="ref-24" ref-type="bibr">Hayajneh, Masaadeh &#x00026; Hayajneh, 2010</xref>). Few studies investigated the risk factors for HBV acquisition in the country and the results pointed to horizontal familial transmission, unhygienic dental care, long-term hemodialysis and living abroad for at least 1 year as the risk factors most frequently associated with the spread of the virus (<xref rid="ref-3" ref-type="bibr">Al Hijazat &#x00026; Ajlouni, 2008</xref>; <xref rid="ref-24" ref-type="bibr">Hayajneh, Masaadeh &#x00026; Hayajneh, 2010</xref>). Similar to countries in the Middle East and North Africa (MENA) region, genotype D appeared to be predominating HBV genotypes in Jordan despite the low number of studies investigating this question (<xref rid="ref-23" ref-type="bibr">Hamoudi, Ghazzawi &#x00026; Hamoudi, 2016</xref>; <xref rid="ref-31" ref-type="bibr">Lin &#x00026; Kao, 2015</xref>; <xref rid="ref-36" ref-type="bibr">Masaadeh, Hayajneh &#x00026; Alqudah, 2008</xref>).</p><p>Phylogenetic inference can be used to investigate the proportion of domestic spread of viruses and to test hypotheses related to variables that are associated with higher likelihood of transmission (<xref rid="ref-32" ref-type="bibr">Lin et al., 2005</xref>; <xref rid="ref-43" ref-type="bibr">Pybus &#x00026; Rambaut, 2009</xref>; <xref rid="ref-46" ref-type="bibr">Sallam et al., 2017</xref>).</p><p>The aim of the current study was to investigate the patterns of HBV <italic>S</italic> gene escape mutants and the antiviral drug resistance mutations among HBV isolates in Jordan. In addition, we aimed to investigate possible risk factors and proportion of local transmission of the virus in the country.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study population</title><p>A total of 76 individuals with chronic HBV infection that were diagnosed between 1984 and 2012 were included in the study. Of those, 56 were followed-up completely till the study closure and provided serum samples. Diagnosis of chronic infection was defined as the presence of hepatitis B surface antigen (HBsAg) for more than six months. Serum samples were collected between 2010 and 2012. Demographic and clinical data were collected and included information on age, gender, year of diagnosis, possible risk factor(s), antiviral drug treatment status and the viral load. The year of study closure was 2012.</p></sec><sec><title>Ethical permission</title><p>The study was approved by the Jordan University Hospital ethical review board (IRB/13/2010) in accordance with the declaration of Helsinki. An informed consent was obtained from all study subjects.</p></sec><sec><title>Viral DNA extraction, amplification and sequencing</title><p>HBV DNA was extracted from serum using a QIAamp DNA blood mini kit (QIAGEN, Hilden, Germany). Spin columns were loaded with 200 &#x003bc;L of serum. Following treatment of samples according to the manufacturer&#x02019;s protocol, HBV DNA was eluted in 40 &#x003bc;L of HyPure water (Thermo Fisher Scientific, Waltham, MA, USA). The <italic>S</italic> region was amplified using primers P1 (nucleotide positions: 1240&#x02013;1260, 5&#x02032;-GCGCTGCAGAAGGTTTGTGGCTCCTCTG-3&#x02032;) and P2 (nucleotide positions: 1928&#x02013;1948, 5&#x02032;-GAGTAACTCCACAGTAGCTCC-3&#x02032;) for the polymerase chain reaction (PCR). The PCR details were as follows: 95 &#x000b0;C for 2 min to activate the enzyme, followed by 35 cycles (denaturation at 95 &#x000b0;C for 30 s, primer annealing at 56 &#x000b0;C for 30 s and elongation 72 &#x000b0;C for 35 s) and finally 10 min at 72 &#x000b0;C. The amplification reaction was performed using a total volume of 25 &#x003bc;L with three &#x003bc;L of DNA template from the extraction in addition to 22 &#x003bc;L of the reaction mix (DNase/RNase free H<sub>2</sub>O 14.4 &#x003bc;L + GoTaq Reaction Buffer 5.0 &#x003bc;L + primer 1 (P1, 100 ng/&#x003bc;L) 1.0 &#x003bc;L + primer 2 (P2, 100 ng/&#x003bc;L) 1.0 &#x003bc;L + 10 &#x003bc;M dNTPs 0.5 &#x003bc;L + GoTaq DNA Polymerase (5U/&#x003bc;L) 0.1 &#x003bc;L using a locally optimized protocol modified from the manufacturer&#x02019;s instructions) (Promega, Madison, WI, USA). A volume of 1.0 &#x003bc;L of the final product was taken for electrophoresis using 1% agarose gel for evaluation of suitability of DNA for sequencing. The expected amplicon size was 700 bp. Prior to sequencing, all PCR products were purified. To ensure a DNA concentration ideal for sequencing, the purified products were titrated by Nanodrop. Sequencing was performed with primers P1 and P2 using a BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) according to manufacturer&#x02019;s instructions through Macrogen commercial sequencing facility (<uri xlink:href="http://foreign.macrogen.co.kr/eng/">http://foreign.macrogen.co.kr/eng/</uri>). Sequence material was assembled using BioEdit software.</p></sec><sec><title>Virus genotyping and mutation analysis</title><p>Genotyping was done using HBV database genotyping tool available online (<uri xlink:href="https://hbvdb.ibcp.fr/HBVdb/">https://hbvdb.ibcp.fr/HBVdb/</uri>). Genotype assignments were confirmed using GenBank BLAST tool and the HBVseq tool from the HIV Drug Resistance Database (<xref rid="ref-48" ref-type="bibr">Shafer, 2006</xref>). Escape mutant analysis and drug resistance analysis were conducted using HIV-GRADE HBV drug resistance interpretation online tool and Geno2pheno (HBV) online tool (<xref rid="ref-38" ref-type="bibr">Neumann-Fraune et al., 2014</xref>; <xref rid="ref-40" ref-type="bibr">Obermeier et al., 2012</xref>).</p></sec><sec><title>Phylogenetic analysis of possible transmission links</title><p>Phylogenetic inference of possible links among the Jordanian sequences was performed using the maximum likelihood (ML) approach as implemented in PhyML 3.0 (<xref rid="ref-22" ref-type="bibr">Guindon et al., 2010</xref>). A search for similar HBV GenBank sequences was done using the BLAST tool, with retention of the best 10 target sequences. The redundant sequences were removed to exclude potential multiple intra-patient sequences, using the Skipredundant tool from EMBOSS package with 0.98 as the similarity cut-off (<xref rid="ref-45" ref-type="bibr">Rice, Longden &#x00026; Bleasby, 2000</xref>). The final dataset comprising the Jordanian sequences with similar reference sequences was subjected to five runs of ML analysis using the GTR + G + I nucleotide substitution model with an estimated proportion of invariable sites (<italic>p</italic> = 0.695). Statistical support of the nodes in phylogenetic trees was estimated using the approximate Likelihood Ratio Test Shimodaira-Hasegawa like (aLRT-SH) with 0.85 as the significance level (<xref rid="ref-5" ref-type="bibr">Anisimova et al., 2011</xref>). The ML tree with the highest likelihood was retained for subsequent analysis.</p></sec><sec><title>Statistical analysis</title><p>The 95% confidence interval of the prevalence (Wilson score interval, binomial distribution) was calculated using EpiTools epidemiological calculator available online (<uri xlink:href="http://epitools.ausvet.com.au">http://epitools.ausvet.com.au</uri>).</p></sec><sec><title>Sequence accession numbers</title><p>A total of 37 sequences analyzed in this study were deposited in GenBank. These sequences were assigned with the following accession numbers: <uri xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/MK033359">MK033359</uri>&#x02013;<uri xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/MK033395">MK033395</uri>.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Characteristics of the study population</title><p>Out of 76 subjects who were initially enrolled in the study, 56 study subjects who were diagnosed with HBV infection at Jordan University Hospital during 2010&#x02013;2012, had serum samples and were included for subsequent analysis. The characteristics of the study subjects are illustrated in (<xref rid="table-1" ref-type="table">Table 1</xref>). A total of 75% of the study subjects were males. The median age at the time of diagnosis was 36 years (mean: 39 years, range: 11&#x02013;77 years). The median time between diagnosis and sampling was 24 months (range: 1&#x02013;312 months, with three study subjects lacking information).</p><table-wrap id="table-1" orientation="portrait" position="float"><object-id pub-id-type="doi">10.7717/peerj.6583/table-1</object-id><label>Table 1</label><caption><title>Characteristics of the hepatitis B virus (HBV) infected individuals included in the study.</title></caption><alternatives><graphic xlink:href="peerj-07-6583-g003"/><table frame="hsides" rules="groups" content-type="text"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="2" colspan="1">Characteristic</th><th colspan="2" rowspan="1">All</th></tr><tr><th rowspan="1" colspan="1"><italic>n</italic><xref ref-type="fn" rid="table-1fn1"><sup>1</sup></xref></th><th rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">56</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Male</td><td rowspan="1" colspan="1">42</td><td rowspan="1" colspan="1">75</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Female</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">25</td></tr><tr><td rowspan="1" colspan="1">Possible risk factor<xref ref-type="fn" rid="table-1fn2"><sup>2</sup></xref></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Familial</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">57</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Blood transfusion</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">11</td></tr><tr><td rowspan="1" colspan="1">&#x02003;IDU</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Unknown</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">27</td></tr><tr><td rowspan="1" colspan="1">Governorate</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Amman</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">45</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Balqa</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">20</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Zarqa</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">16</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Madaba</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Ma&#x02019;an</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Karak</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mafraq</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Unknown</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-1fn"><p><bold>Notes:</bold></p></fn><fn id="table-1fn1" fn-type="other"><label>1</label><p><italic>n</italic>, number.</p></fn><fn id="table-1fn2" fn-type="other"><label>2</label><p>IDU, injection drug use.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Determination of HBV genotype</title><p>The HBV RT sequences that were utilized in our study were generated using the Sanger population sequencing method. We were able to successfully obtain a total of 37 sequences (66% success rate) with open reading frames each having a final length of 573 bp (RT domain codons: 25&#x02013;217; HBs antigen (SHB protein) codons: 17&#x02013;208). All Jordanian HBV sequences were of genotype D using the various genotyping analysis tools. Further analysis based on Geno2pheno (HBV) 2.0 and GenBank blast tools revealed that all Jordanian sequences were of sub-genotype D1. Of the 37 HBV sequences characterized in our study, 10 sequences (27%) were retrieved from individuals who were treatment-na&#x000ef;ve, 10 sequences (27%) were retrieved from individuals with chronic HBV infection that underwent treatment.</p></sec><sec><title>RT mutation analysis</title><p>Using the Geno2pheno HBV drug resistance tool and HIV grade HBV drug resistance interpretation tool, three patients (8.1% (95% CI [2.8&#x02013;21.3])), were found to harbor at least a single RT mutation conferring possible or confirmed resistance to RT inhibitors. The details of these mutations are in (<xref rid="table-2" ref-type="table">Table 2</xref>). The first patient was a male with history of treatment with lamivudine who had mutations at established drug resistance positions: L180M, T184A, M204V which confer resistance to lamivudine, entecavir and telbivudine. The second patient was a female with unknown history of treatment who had mutations at established drug resistance positions: L180M, M204V which confer resistance to lamivudine, telbivudine and partial resistance to entecavir. The third patient was a male with history of treatment with lamivudine who had mutations at established drug resistance positions: V173L, L180M, M204V which confer resistance to lamivudine, telbivudine and partial resistance to entecavir.</p><table-wrap id="table-2" orientation="portrait" position="float"><object-id pub-id-type="doi">10.7717/peerj.6583/table-2</object-id><label>Table 2</label><caption><title>The distribution of reverse transcriptase (RT) mutations and HBsAg vaccine escape mutations among the study population.</title></caption><alternatives><graphic xlink:href="peerj-07-6583-g004"/><graphic xlink:href="peerj-07-6583-g005"/><table frame="hsides" rules="groups" content-type="text"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Sample ID</th><th rowspan="1" colspan="1">Age</th><th rowspan="1" colspan="1">Gender</th><th rowspan="1" colspan="1">Year of Dx<xref ref-type="fn" rid="table-2fn2"><sup>1</sup></xref></th><th rowspan="1" colspan="1">Sub-genotype</th><th rowspan="1" colspan="1">Rx status<xref ref-type="fn" rid="table-2fn3"><sup>2</sup></xref></th><th rowspan="1" colspan="1">Mutations RT<xref ref-type="fn" rid="table-2fn4"><sup>3</sup></xref></th><th rowspan="1" colspan="1">Escape mutations</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2009</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Na&#x000ef;ve</td><td rowspan="1" colspan="1">N53S, F122I, H124D, Y135S, H216L, L217F</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2009</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">Y135S, H216L, L217F</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">84</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">F122I, H124Y, Y135S, H216L, L217F</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">97</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">1995</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Na&#x000ef;ve</td><td rowspan="1" colspan="1">R110G, Y135S, H216L</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">68</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2009</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">F122I, H124Y, Y135S, H216L</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">66</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2004</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">H124Y, Y135S, I163V, H216I, L217F</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">85</td><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">2004</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Na&#x000ef;ve</td><td rowspan="1" colspan="1">S119P, H124Y, Y135S, H216L</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">99</td><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2007</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Experienced (Lamivudine)</td><td rowspan="1" colspan="1">F122I, H124Y, Y135S, L217F</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2006</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Na&#x000ef;ve</td><td rowspan="1" colspan="1">L91I, H124Y, N131D, Y135S, H216L, L217F</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">2009</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Experienced (Lamivudine)</td><td rowspan="1" colspan="1">Y135S, H216I, L217F</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">1998</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Experienced (Lamivudine)</td><td rowspan="1" colspan="1">H124Y, Y135S, Q215H, H216L</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">101</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2010</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">F122I, H124Y, Y135S, H216L, L217F</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2009</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Experienced (Lamivudine)</td><td rowspan="1" colspan="1">Y135S, H216L, L217F</td><td rowspan="1" colspan="1">R122K</td></tr><tr><td rowspan="1" colspan="1">46</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">2000</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Experienced (Lamivudine)</td><td rowspan="1" colspan="1">H124Y, Y135S, Q215H, H216F, L217W</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">57</td><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">2010</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">A38E, Y54H, M129L, Y135S, V173L, H216L</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">87</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2011</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">K32M, Y135S, S213T, H216I</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">106</td><td rowspan="1" colspan="1">47</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2011</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">F122I, H124Y, Y135S, H216L</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2009</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Experienced (Lamivudine)</td><td rowspan="1" colspan="1">H124Y, Y135S, Q149K, H216L</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">49</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">2008</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">S85A, Y135S, N139D, L199V, H216I, L217W</td><td rowspan="1" colspan="1">L109R</td></tr><tr><td rowspan="1" colspan="1">76</td><td rowspan="1" colspan="1">51</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">2009</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Na&#x000ef;ve</td><td rowspan="1" colspan="1">L91I, H124D, Y135S, K212N, H216P</td><td rowspan="1" colspan="1">S143L</td></tr><tr><td rowspan="1" colspan="1">81</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">1998</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Experienced (Lamivudine)</td><td rowspan="1" colspan="1">S78T, F122I, H124Y, Y135S, H216I</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">83</td><td rowspan="1" colspan="1">51</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2000</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">A38E, R110G, F122I, H124Y, Y135S, Q149K, S176T, S185I, H197P, C198R, S202I, V208I, A211G, K212G, S213Q, V214Y, Q215L, H216L, L217F</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2009</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Experienced (Lamivudine)</td><td rowspan="1" colspan="1">Y135S, H216L, L217F</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">34</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2008</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">F122I, H124Y, Y135S, H216L</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2009</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Na&#x000ef;ve</td><td rowspan="1" colspan="1">H124Y, Y135S, H216P</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">70</td><td rowspan="1" colspan="1">44</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2011</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Na&#x000ef;ve</td><td rowspan="1" colspan="1">Y54G, N76D, Y135S, Y141F, H216I, L217F</td><td rowspan="1" colspan="1">M133L</td></tr><tr><td rowspan="1" colspan="1">89</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2009</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">Y54H, Y135S, H216L</td><td rowspan="1" colspan="1">D144E</td></tr><tr><td rowspan="1" colspan="1">105</td><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">2011</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Na&#x000ef;ve</td><td rowspan="1" colspan="1">H124Y, T128P, Y135S, L145M, H216P</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">1984</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Experienced (Lamivudine)</td><td rowspan="1" colspan="1">A38E, Y54H, H124Y, M129L, Y135S, <bold>V173L</bold>, <bold>L180M</bold>, <bold>M204V</bold>, H216L</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2009</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">S109P, Y135S, H216L, L217F</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">56</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2010</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">T37A, F122L, N123D, Y135S, H216L</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">77</td><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2011</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Na&#x000ef;ve</td><td rowspan="1" colspan="1">H124Y, Y135S, G152K, K154N, I187L, H216P, L217F</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">103</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">2011</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Na&#x000ef;ve</td><td rowspan="1" colspan="1">N53K, F122I, H124Y, Y135S, H216L</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">63</td><td rowspan="1" colspan="1">77</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2004</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">H124Y, Y135S, Q215H, H216T, L217F</td><td rowspan="1" colspan="1">R122K</td></tr><tr><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">34</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">2007</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">F122I, H124Y, Y135S, H216I, L217W</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">58</td><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">2006</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">V27A, A38E, S117N, N118D, H124D, Y135S, S137T, <bold>L180M</bold>, <bold>M204V</bold>, H216L</td><td rowspan="1" colspan="1">R122K, Q129R</td></tr><tr><td rowspan="1" colspan="1">104</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2007</td><td rowspan="1" colspan="1">D1</td><td rowspan="1" colspan="1">Experienced (Lamivudine)</td><td rowspan="1" colspan="1">A38E, H124Y, Y135S, <bold>L180M</bold>, <bold>T184A</bold>, <bold>M204V</bold>, H216I</td><td rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-2fn"><p><bold>Notes:</bold></p></fn><fn id="table-2fn1" fn-type="other"><p>RT mutation conferring possible or confirmed resistance to RT inhibitors are highlighted in bold.</p></fn><fn id="table-2fn2" fn-type="other"><label>1</label><p>Dx, diagnosis.</p></fn><fn id="table-2fn3" fn-type="other"><label>2</label><p>Rx, treatment.</p></fn><fn id="table-2fn4" fn-type="other"><label>3</label><p>RT, reverse transcriptase.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>HBsAg escape mutations</title><p>The overall prevalence of typical HBsAg escape mutants was 18.9% (95% CI [9.5&#x02013;34.2]). The R122K mutation which affects HBV detection was found in three patients. The L109R mutation that is a vaccine-escape mutant was found in a single patient. The S143L mutation which is both a vaccine-escape mutant and affects HBV detection was found in a single patient. The M133L and D144E mutations that are vaccine-escape mutants, affecting HBV detection and immunoglobulin therapy were found each in a single patient. Finally, a single patient had Q129R mutation that is a vaccine-escape mutant and affects HBV detection besides the R122K mutation.</p></sec><sec><title>Possible domestic transmission of HBV in Jordan</title><p>To estimate the proportion of HBV sequences that are possibly linked in transmission clusters indicating domestic transmission, ML analysis was conducted which revealed that the proportion of phylogenetic clustering was 29.7% (11 of the 37 Jordanian sequences; <xref ref-type="fig" rid="fig-1">Fig. 1</xref>). The clustering sequences were distributed among a dyad (two sequences) and a network of 10 sequences (with nine Jordanian sequences and a single Israeli sequence). The non-clustering Jordanian sequences were present in supported monophyletic clades together with sequences that were collected in Iran, Turkey, Syria and Egypt (<xref ref-type="fig" rid="fig-1">Fig. 1</xref>).</p><fig id="fig-1" orientation="portrait" position="float"><object-id pub-id-type="doi">10.7717/peerj.6583/fig-1</object-id><label>Figure 1</label><caption><title>Maximum likelihood tree of the Jordanian HBV sequences with similar GenBank sequences.</title><p>The Jordanian sequence names are highlighted in blue color. The statistically supported branches (with approximate Likelihood Ratio Test Shimodaira-Hasegawa like values &#x02265; 0.85) are highlighted in red color. The GenBank sequences collected in the Middle East and North Africa (MENA) region are highlighted in green color.</p></caption><graphic xlink:href="peerj-07-6583-g001"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The epidemiological and antiviral drug resistance data of HBV in Jordan are limited. The results of our study are strengthened by the good coverage of sampling from different regions in the country (<xref ref-type="fig" rid="fig-2">Fig. 2</xref>). Genotyping results showed that subgenotype D1 was found exclusively, which is consistent with previous studies from Jordan and the MENA region where this sub-genotype predominates (<xref rid="ref-1" ref-type="bibr">Abdelnabi et al., 2014</xref>; <xref rid="ref-2" ref-type="bibr">Al Baqlani et al., 2014</xref>; <xref rid="ref-6" ref-type="bibr">Asaad et al., 2015</xref>; <xref rid="ref-13" ref-type="bibr">Ciccozzi et al., 2014</xref>; <xref rid="ref-18" ref-type="bibr">El-Mowafy et al., 2017</xref>; <xref rid="ref-23" ref-type="bibr">Hamoudi, Ghazzawi &#x00026; Hamoudi, 2016</xref>; <xref rid="ref-62" ref-type="bibr">Ziaee et al., 2016</xref>). The finding that all HBV isolates in our study were exclusively of genotype D is possibly related to origins of infections in the MENA in which genotype D predominates. This is supported by the finding of intermingling of sequences from Iran, Turkey, Syria and Saudi Arabia (<xref ref-type="fig" rid="fig-1">Fig. 1</xref>).</p><fig id="fig-2" orientation="portrait" position="float"><object-id pub-id-type="doi">10.7717/peerj.6583/fig-2</object-id><label>Figure 2</label><caption><title>Hepatitis B virus sample distribution from different Jordanian governorates.</title><p>The diameter of each circle is proportional to the number of samples; Amman: 25, Balqa: 11, Zarqa: 9, Madaba: 3, Ma&#x02019;an: 3, Karak: 3, Mafraq: 1. The map was retrieved from Wikimedia commons available at: (<uri xlink:href="https://upload.wikimedia.org/wikipedia/commons/6/6e/Jordan_location_map.svg">https://upload.wikimedia.org/wikipedia/commons/6/6e/Jordan_location_map.svg</uri>).</p></caption><graphic xlink:href="peerj-07-6583-g002"/></fig><p>In the current study, we investigated the patterns of HBsAg escape mutants and HBV RT mutations for the first time in Jordan to the best of our knowledge. The prevalence of HBsAg escape mutants in Jordan was 18.9%, with the R122K mutation which affects HBV detection being the most prevalent type. This is comparable to a study done in Iran, which showed that the frequency of 14% major hydrophilic region mutations (MHR), with the most frequent ones of P120T/S and R122K/T (<xref rid="ref-37" ref-type="bibr">Moradi et al., 2012</xref>). In Turkey, the most frequent mutations observed were T143M and K122R, whereas in Egypt 14.8% presented with mutations in the MHR, and eight different mutations were discovered: R122K, S143L, L109P, S114P, S117N, P127S, P127T and Y134F (<xref rid="ref-59" ref-type="bibr">Zeid, Ramadan &#x00026; Shemis, 2016</xref>). Previous studies have shown the significance of R122 as a serologic determinant for HBV subtype, with subsequent effect on the antigenicity and immunogenicity of the virus (<xref rid="ref-7" ref-type="bibr">Ashton-Rickardt &#x00026; Murray, 1989</xref>; <xref rid="ref-25" ref-type="bibr">Hou et al., 2001</xref>; <xref rid="ref-55" ref-type="bibr">Wu et al., 2012</xref>).</p><p>The mutations in the HBV RT have been shown to affect the management of HBV infection (<xref rid="ref-12" ref-type="bibr">Caligiuri et al., 2016</xref>; <xref rid="ref-54" ref-type="bibr">Terrault et al., 2016</xref>). For instance, the patients in our study sample who developed HBV RT mutations showed complete or partial resistance to treatment by lamivudine, telbivudine and entecavir. In the three patients with lamivudine resistance mutations, partial or complete resistance to entecavir was detected which is likely related to selection of HBV entecavir mutants in those patients. This finding is in line with recent findings by <xref rid="ref-20" ref-type="bibr">Geipel et al. (2015)</xref>.</p><p>The most common resistance mutations in Jordan were 180M and 204V, which were always present as co-mutations. Other identified mutations were 173L and 184A mutations, and they were co-mutated with 180M, 204V. M204I/V mutations are frequently accompanied by compensatory mutations in other domains such as 59 rtV173L, rtL180M, rtT184S/G, 58 rtI169T, rtS202I, rtL80V/I and rtQ215S which enhanced the replication efficiency of rt204I/V mutants without significantly affecting lamivudine resistance, by compensating the decrease in efficiency due to resistance-associated changes (<xref rid="ref-8" ref-type="bibr">Bartholomeusz &#x00026; Locarnini, 2006a</xref>, <xref rid="ref-9" ref-type="bibr">2006b</xref>; <xref rid="ref-12" ref-type="bibr">Caligiuri et al., 2016</xref>; <xref rid="ref-63" ref-type="bibr">Zoulim &#x00026; Locarnini, 2009</xref>). For example, dual rtL180M and M204V/I mutants were frequently found in patients in Italy, with three patients having triple mutation of rtV173L, rtL180M and M204V (<xref rid="ref-44" ref-type="bibr">Quiros-Roldan et al., 2008</xref>). Upon comparing the mutant strains with wild HBV strains, patients with rtM204V/I more frequently presented with severe acute hepatitis B and lower serum HBV DNA values (<xref rid="ref-15" ref-type="bibr">Coppola et al., 2013</xref>).</p><p>A recent meta-analysis has shown that the incidence of spontaneous primary and secondary mutations among untreated chronic hepatitis B patients was 4.9% for primary mutations of rtM204V/I, while the natural incidence of secondary rtL180M mutations was 2.7% (<xref rid="ref-60" ref-type="bibr">Zhang et al., 2015</xref>). Previous literature suggests that lamivudine is the main cause of YMDD (tyrosine-methionine-aspartateaspartate) mutations (M204I/V) within the catalytic sites (C domain) in HBV P-ORF (<xref rid="ref-12" ref-type="bibr">Caligiuri et al., 2016</xref>; <xref rid="ref-27" ref-type="bibr">Ji et al., 2011</xref>). In Turkey, Japan and China, the a high rates of spontaneous YMDD mutation may increase the unresponsiveness to lamivudine, leading to prolonged therapy time and extra cost (<xref rid="ref-60" ref-type="bibr">Zhang et al., 2015</xref>), for which we need to perform further studies to investigate the probability of development of antiviral resistant mutants worldwide, and to study the effects of the infection with mutant viruses on the clinical course of the disease.</p><p>Upon conducting ML analysis to investigate the possibility of domestic transmission of HBV in Jordan, the proportion of phylogenetic clustering was 29.7%. Horizontal transmission is the main mode of transmission of HBV in Jordan (<xref rid="ref-4" ref-type="bibr">Andr&#x000e9;, 2000</xref>). Clustering of chronic HBV infections within the family is common in areas of where HBV is endemic, and horizontal transmission during early childhood is a major route of HBV transmission (<xref rid="ref-17" ref-type="bibr">Dumpis et al., 2001</xref>; <xref rid="ref-32" ref-type="bibr">Lin et al., 2005</xref>; <xref rid="ref-58" ref-type="bibr">Zampino et al., 2002</xref>). The high proportion of clustering among the study subjects highlights the need for intervention measures by public health control strategies to stop the chains of forward transmission of the virus.</p><p>Several caveats of our study should be addressed including the low sampling coverage and the short length of RT sequences that were used to conduct the transmission cluster analysis. The study was closed in 2012, which highlights the need for a follow up study to assess the recent trends of genotype and risk factors for HBV infection in the country. Another caveat of our study is the lack of clinical and serological data from the study subjects.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>To conclude, we investigated the genotype distribution, risk factors, RT and HBsAg vaccine escape mutations and the transmission of HBV in Jordan over a large area of the country. Based on the findings of our study, we recommend RT mutation analysis before the initiation of therapy in patients with chronic HBV infection in Jordan. Lamivudine monotherapy is strongly discouraged due to high risk of resistance development. In addition, the relatively high proportion of phylogenetic clustering highlights the need for public health control measures to prevent forward transmission of the virus in the country and regionally.</p></sec><sec sec-type="supplementary-material" id="supplemental-information"><title>Supplemental Information</title><supplementary-material content-type="local-data" id="supp-1"><object-id pub-id-type="doi">10.7717/peerj.6583/supp-1</object-id><label>Supplemental Information 1</label><caption><title>Nucleotide HBV sequences that were generated for the study.</title></caption><media xlink:href="peerj-07-6583-s001.txt"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><sec sec-type="additional-information"><title>Additional Information and Declarations</title><fn-group content-type="competing-interests"><title>Competing Interests</title><fn fn-type="COI-statement" id="conflict-1"><p>The authors declare that they have no competing interests.</p></fn></fn-group><fn-group content-type="author-contributions"><title>Author Contributions</title><fn fn-type="con" id="contribution-1"><p><xref ref-type="contrib" rid="author-1">Nidaa A. Ababneh</xref> conceived and designed the experiments, performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft, DNA Extraction, PCR and DNA Sequencing.</p></fn><fn fn-type="con" id="contribution-2"><p><xref ref-type="contrib" rid="author-2">Malik Sallam</xref> conceived and designed the experiments, performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.</p></fn><fn fn-type="con" id="contribution-3"><p><xref ref-type="contrib" rid="author-3">Doaa Kaddomi</xref> approved the final draft, sample and Clinical Data Collection.</p></fn><fn fn-type="con" id="contribution-4"><p><xref ref-type="contrib" rid="author-4">Abdelrahman M. Attili</xref> approved the final draft, sample and Clinical Data Collection.</p></fn><fn fn-type="con" id="contribution-5"><p><xref ref-type="contrib" rid="author-5">Isam Bsisu</xref> authored or reviewed drafts of the paper, approved the final draft.</p></fn><fn fn-type="con" id="contribution-6"><p><xref ref-type="contrib" rid="author-6">Nadia Khamees</xref> approved the final draft, sample and Clinical Data Collection.</p></fn><fn fn-type="con" id="contribution-7"><p><xref ref-type="contrib" rid="author-7">Amer Khatib</xref> approved the final draft, sample and Clinical Data Collection.</p></fn><fn fn-type="con" id="contribution-8"><p><xref ref-type="contrib" rid="author-8">Azmi Mahafzah</xref> conceived and designed the experiments, analyzed the data, contributed reagents/materials/analysis tools, authored or reviewed drafts of the paper, approved the final draft, supervision, Funding Acquisition.</p></fn></fn-group><fn-group content-type="other"><title>Human Ethics</title><fn id="addinfo-1"><p>The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):</p><p>The study was approved by the Jordan University Hospital ethical review board (IRB/13/2010) in accordance with the Declaration of Helsinki. An informed consent was obtained from all patients.</p></fn></fn-group><fn-group content-type="other"><title>Data Availability</title><fn id="addinfo-3"><p>The following information was supplied regarding data availability:</p><p>A complete list of the nucleotide sequences that were generated for the study are available in <xref ref-type="supplementary-material" rid="supplemental-information">Supplemental File 1</xref>.</p></fn></fn-group></sec><ref-list content-type="authoryear"><title>References</title><ref id="ref-1"><label>Abdelnabi et al. (2014)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelnabi</surname><given-names>Z</given-names></name><name><surname>Saleh</surname><given-names>N</given-names></name><name><surname>Baraghithi</surname><given-names>S</given-names></name><name><surname>Glebe</surname><given-names>D</given-names></name><name><surname>Azzeh</surname><given-names>M</given-names></name></person-group><article-title>Subgenotypes and mutations in the S and polymerase genes of hepatitis B virus carriers in the West Bank, Palestine</article-title><source>PLOS ONE</source><year>2014</year><volume>9</volume><issue>12</issue><elocation-id>e113821</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0113821</pub-id><pub-id pub-id-type="pmid">25503289</pub-id></element-citation></ref><ref id="ref-2"><label>Al Baqlani et al. (2014)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Baqlani</surname><given-names>SA</given-names></name><name><surname>Sy</surname><given-names>BT</given-names></name><name><surname>Ratsch</surname><given-names>BA</given-names></name><name><surname>Al Naamani</surname><given-names>K</given-names></name><name><surname>Al Awaidy</surname><given-names>S</given-names></name><name><surname>Busaidy</surname><given-names>SA</given-names></name><name><surname>Pauli</surname><given-names>G</given-names></name><name><surname>Bock</surname><given-names>CT</given-names></name></person-group><article-title>Molecular epidemiology and genotyping of hepatitis B virus of HBsAg-positive patients in Oman</article-title><source>PLOS ONE</source><year>2014</year><volume>9</volume><issue>5</issue><elocation-id>e97759</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0097759</pub-id><pub-id pub-id-type="pmid">24835494</pub-id></element-citation></ref><ref id="ref-3"><label>Al Hijazat &#x00026; Ajlouni (2008)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Hijazat</surname><given-names>M</given-names></name><name><surname>Ajlouni</surname><given-names>YM</given-names></name></person-group><article-title>Hepatitis B infection among patients receiving chronic hemodialysis at the Royal Medical Services in Jordan</article-title><source>Saudi Journal of Kidney Diseases and Transplantation</source><year>2008</year><volume>19</volume><issue>2</issue><fpage>260</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">18310881</pub-id></element-citation></ref><ref id="ref-4"><label>Andr&#x000e9; (2000)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andr&#x000e9;</surname><given-names>F</given-names></name></person-group><article-title>Hepatitis B epidemiology in Asia, the middle East and Africa</article-title><source>Vaccine</source><year>2000</year><volume>18</volume><fpage>S20</fpage><lpage>S22</lpage><pub-id pub-id-type="doi">10.1016/s0264-410x(99)00456-9</pub-id><pub-id pub-id-type="pmid">10683538</pub-id></element-citation></ref><ref id="ref-5"><label>Anisimova et al. (2011)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anisimova</surname><given-names>M</given-names></name><name><surname>Gil</surname><given-names>M</given-names></name><name><surname>Dufayard</surname><given-names>JF</given-names></name><name><surname>Dessimoz</surname><given-names>C</given-names></name><name><surname>Gascuel</surname><given-names>O</given-names></name></person-group><article-title>Survey of branch support methods demonstrates accuracy, power, and robustness of fast likelihood-based approximation schemes</article-title><source>Systematic Biology</source><year>2011</year><volume>60</volume><issue>5</issue><fpage>685</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1093/sysbio/syr041</pub-id><pub-id pub-id-type="pmid">21540409</pub-id></element-citation></ref><ref id="ref-6"><label>Asaad et al. (2015)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asaad</surname><given-names>AM</given-names></name><name><surname>Al-Ayed</surname><given-names>MS</given-names></name><name><surname>Aleraky</surname><given-names>M</given-names></name><name><surname>Qureshi</surname><given-names>MA</given-names></name></person-group><article-title>Hepatitis B virus genotyping in chronic hepatitis B patients in southwestern Saudi Arabia</article-title><source>Brazilian Journal of Infectious Diseases</source><year>2015</year><volume>19</volume><issue>5</issue><fpage>525</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1016/j.bjid.2015.03.007</pub-id><pub-id pub-id-type="pmid">25997779</pub-id></element-citation></ref><ref id="ref-7"><label>Ashton-Rickardt &#x00026; Murray (1989)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashton-Rickardt</surname><given-names>PG</given-names></name><name><surname>Murray</surname><given-names>K</given-names></name></person-group><article-title>Mutations that change the immunological subtype of hepatitis B virus surface antigen and distinguish between antigenic and immunogenic determination</article-title><source>Journal of Medical Virology</source><year>1989</year><volume>29</volume><issue>3</issue><fpage>204</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1002/jmv.1890290311</pub-id><pub-id pub-id-type="pmid">2693611</pub-id></element-citation></ref><ref id="ref-8"><label>Bartholomeusz &#x00026; Locarnini (2006a)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartholomeusz</surname><given-names>A</given-names></name><name><surname>Locarnini</surname><given-names>S</given-names></name></person-group><article-title>Hepatitis B virus mutations associated with antiviral therapy</article-title><source>Journal of Medical Virology</source><year>2006a</year><volume>78</volume><issue>S1</issue><fpage>S52</fpage><lpage>S55</lpage><pub-id pub-id-type="doi">10.1002/jmv.20608</pub-id><pub-id pub-id-type="pmid">16622878</pub-id></element-citation></ref><ref id="ref-9"><label>Bartholomeusz &#x00026; Locarnini (2006b)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartholomeusz</surname><given-names>A</given-names></name><name><surname>Locarnini</surname><given-names>SA</given-names></name></person-group><article-title>Antiviral drug resistance: clinical consequences and molecular aspects</article-title><source>Semin Liver Dis</source><year>2006b</year><volume>26</volume><issue>2</issue><fpage>162</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1055/s-2006-939758</pub-id><pub-id pub-id-type="pmid">16673294</pub-id></element-citation></ref><ref id="ref-10"><label>Batayneh &#x00026; Bdour (2002)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batayneh</surname><given-names>N</given-names></name><name><surname>Bdour</surname><given-names>S</given-names></name></person-group><article-title>Risk of perinatal transmission of hepatitis B virus in Jordan</article-title><source>Infectious Diseases in Obstetrics and Gynecology</source><year>2002</year><volume>10</volume><issue>3</issue><fpage>127</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1155/S1064744902000121</pub-id><pub-id pub-id-type="pmid">12625968</pub-id></element-citation></ref><ref id="ref-11"><label>Bock et al. (2002)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bock</surname><given-names>CT</given-names></name><name><surname>Tillmann</surname><given-names>HL</given-names></name><name><surname>Torresi</surname><given-names>J</given-names></name><name><surname>Klempnauer</surname><given-names>J</given-names></name><name><surname>Locarnini</surname><given-names>S</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name><name><surname>Trautwein</surname><given-names>C</given-names></name></person-group><article-title>Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation</article-title><source>Gastroenterology</source><year>2002</year><volume>122</volume><issue>2</issue><fpage>264</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1053/gast.2002.31015</pub-id><pub-id pub-id-type="pmid">11832441</pub-id></element-citation></ref><ref id="ref-12"><label>Caligiuri et al. (2016)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caligiuri</surname><given-names>P</given-names></name><name><surname>Cerruti</surname><given-names>R</given-names></name><name><surname>Icardi</surname><given-names>G</given-names></name><name><surname>Bruzzone</surname><given-names>B</given-names></name></person-group><article-title>Overview of hepatitis B virus mutations and their implications in the management of infection</article-title><source>World Journal of Gastroenterology</source><year>2016</year><volume>22</volume><issue>1</issue><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.3748/wjg.v22.i1.145</pub-id><pub-id pub-id-type="pmid">26755866</pub-id></element-citation></ref><ref id="ref-13"><label>Ciccozzi et al. (2014)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciccozzi</surname><given-names>M</given-names></name><name><surname>Ciccaglione</surname><given-names>AR</given-names></name><name><surname>Lo Presti</surname><given-names>A</given-names></name><name><surname>Equestre</surname><given-names>M</given-names></name><name><surname>Cella</surname><given-names>E</given-names></name><name><surname>Ebranati</surname><given-names>E</given-names></name><name><surname>Gabanelli</surname><given-names>E</given-names></name><name><surname>Villano</surname><given-names>U</given-names></name><name><surname>Bruni</surname><given-names>R</given-names></name><name><surname>Yalcinkaya</surname><given-names>T</given-names></name><name><surname>Tanzi</surname><given-names>E</given-names></name><name><surname>Zehender</surname><given-names>G</given-names></name></person-group><article-title>Evolutionary dynamics of HBV-D1 genotype epidemic in Turkey</article-title><source>Journal of Medical Virology</source><year>2014</year><volume>86</volume><issue>1</issue><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1002/jmv.23740</pub-id><pub-id pub-id-type="pmid">24243521</pub-id></element-citation></ref><ref id="ref-14"><label>Coppola et al. (2015)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coppola</surname><given-names>N</given-names></name><name><surname>Onorato</surname><given-names>L</given-names></name><name><surname>Minichini</surname><given-names>C</given-names></name><name><surname>Di Caprio</surname><given-names>G</given-names></name><name><surname>Starace</surname><given-names>M</given-names></name><name><surname>Sagnelli</surname><given-names>C</given-names></name><name><surname>Sagnelli</surname><given-names>E</given-names></name></person-group><article-title>Clinical significance of hepatitis B surface antigen mutants</article-title><source>World Journal of Hepatology</source><year>2015</year><volume>7</volume><issue>27</issue><fpage>2729</fpage><lpage>2739</lpage><pub-id pub-id-type="doi">10.4254/wjh.v7.i27.2729</pub-id><pub-id pub-id-type="pmid">26644816</pub-id></element-citation></ref><ref id="ref-15"><label>Coppola et al. (2013)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coppola</surname><given-names>N</given-names></name><name><surname>Tonziello</surname><given-names>G</given-names></name><name><surname>Colombatto</surname><given-names>P</given-names></name><name><surname>Pisaturo</surname><given-names>M</given-names></name><name><surname>Messina</surname><given-names>V</given-names></name><name><surname>Moriconi</surname><given-names>F</given-names></name><name><surname>Alessio</surname><given-names>L</given-names></name><name><surname>Sagnelli</surname><given-names>C</given-names></name><name><surname>Cavallone</surname><given-names>D</given-names></name><name><surname>Brunetto</surname><given-names>M</given-names></name></person-group><article-title>Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B</article-title><source>Journal of Infection</source><year>2013</year><volume>67</volume><issue>4</issue><fpage>322</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2013.06.006</pub-id><pub-id pub-id-type="pmid">23796869</pub-id></element-citation></ref><ref id="ref-16"><label>Croagh, Desmond &#x00026; Bell (2015)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croagh</surname><given-names>CM</given-names></name><name><surname>Desmond</surname><given-names>PV</given-names></name><name><surname>Bell</surname><given-names>SJ</given-names></name></person-group><article-title>Genotypes and viral variants in chronic hepatitis B: a review of epidemiology and clinical relevance</article-title><source>World Journal of Hepatology</source><year>2015</year><volume>7</volume><issue>3</issue><fpage>289</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.4254/wjh.v7.i3.289</pub-id><pub-id pub-id-type="pmid">25848459</pub-id></element-citation></ref><ref id="ref-17"><label>Dumpis et al. (2001)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumpis</surname><given-names>U</given-names></name><name><surname>Holmes</surname><given-names>EC</given-names></name><name><surname>Mendy</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Thursz</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>A</given-names></name><name><surname>Whittle</surname><given-names>H</given-names></name><name><surname>Karayiannis</surname><given-names>P</given-names></name></person-group><article-title>Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis</article-title><source>Journal of Hepatology</source><year>2001</year><volume>35</volume><issue>1</issue><fpage>99</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/s0168-8278(01)00064-2</pub-id><pub-id pub-id-type="pmid">11495049</pub-id></element-citation></ref><ref id="ref-18"><label>El-Mowafy et al. (2017)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Mowafy</surname><given-names>M</given-names></name><name><surname>Elgaml</surname><given-names>A</given-names></name><name><surname>El-Mesery</surname><given-names>M</given-names></name><name><surname>Elegezy</surname><given-names>M</given-names></name></person-group><article-title>Molecular analysis of Hepatitis B virus sub-genotypes and incidence of preS1/preS2 region mutations in HBV-infected Egyptian patients from Mansoura</article-title><source>Journal of Medical Virology</source><year>2017</year><volume>89</volume><issue>9</issue><fpage>1559</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.1002/jmv.24828</pub-id><pub-id pub-id-type="pmid">28390175</pub-id></element-citation></ref><ref id="ref-19"><label>Fares &#x00026; Holmes (2002)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fares</surname><given-names>MA</given-names></name><name><surname>Holmes</surname><given-names>EC</given-names></name></person-group><article-title>A revised evolutionary history of hepatitis B virus (HBV)</article-title><source>Journal of Molecular Evolution</source><year>2002</year><volume>54</volume><issue>6</issue><fpage>807</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1007/s00239-001-0084-z</pub-id><pub-id pub-id-type="pmid">12029362</pub-id></element-citation></ref><ref id="ref-20"><label>Geipel et al. (2015)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geipel</surname><given-names>A</given-names></name><name><surname>Seiz</surname><given-names>PL</given-names></name><name><surname>Niekamp</surname><given-names>H</given-names></name><name><surname>Neumann-Fraune</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Kaiser</surname><given-names>R</given-names></name><name><surname>Protzer</surname><given-names>U</given-names></name><name><surname>Gerlich</surname><given-names>WH</given-names></name><name><surname>Glebe</surname><given-names>D</given-names></name><name><surname>Consortium</surname><given-names>H</given-names></name></person-group><article-title>Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine</article-title><source>Antiviral Therapy</source><year>2015</year><volume>20</volume><issue>8</issue><fpage>779</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.3851/IMP2928</pub-id><pub-id pub-id-type="pmid">25560463</pub-id></element-citation></ref><ref id="ref-22"><label>Guindon et al. (2010)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guindon</surname><given-names>S</given-names></name><name><surname>Dufayard</surname><given-names>JF</given-names></name><name><surname>Lefort</surname><given-names>V</given-names></name><name><surname>Anisimova</surname><given-names>M</given-names></name><name><surname>Hordijk</surname><given-names>W</given-names></name><name><surname>Gascuel</surname><given-names>O</given-names></name></person-group><article-title>New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0</article-title><source>Systematic Biology</source><year>2010</year><volume>59</volume><issue>3</issue><fpage>307</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1093/sysbio/syq010</pub-id><pub-id pub-id-type="pmid">20525638</pub-id></element-citation></ref><ref id="ref-23"><label>Hamoudi, Ghazzawi &#x00026; Hamoudi (2016)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamoudi</surname><given-names>W</given-names></name><name><surname>Ghazzawi</surname><given-names>I</given-names></name><name><surname>Hamoudi</surname><given-names>MMY</given-names></name></person-group><article-title>Hepatitis B genotypic and serologic characteristics in Jordan</article-title><source>Journal of the Royal Medical Services</source><year>2016</year><volume>23</volume><issue>4</issue><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.12816/0032196</pub-id></element-citation></ref><ref id="ref-24"><label>Hayajneh, Masaadeh &#x00026; Hayajneh (2010)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayajneh</surname><given-names>WA</given-names></name><name><surname>Masaadeh</surname><given-names>HA</given-names></name><name><surname>Hayajneh</surname><given-names>YA</given-names></name></person-group><article-title>A case-control study of risk factors for hepatitis B virus infection in North Jordan</article-title><source>Journal of Medical Virology</source><year>2010</year><volume>82</volume><issue>2</issue><fpage>220</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1002/jmv.21603</pub-id><pub-id pub-id-type="pmid">20029796</pub-id></element-citation></ref><ref id="ref-25"><label>Hou et al. (2001)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Lau</surname><given-names>GK</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Waters</surname><given-names>J</given-names></name><name><surname>Karayiannis</surname><given-names>P</given-names></name><name><surname>Luo</surname><given-names>K</given-names></name></person-group><article-title>Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen&#x02013;negative Chinese carriers</article-title><source>Hepatology</source><year>2001</year><volume>34</volume><issue>5</issue><fpage>1027</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1053/jhep.2001.28708</pub-id><pub-id pub-id-type="pmid">11679975</pub-id></element-citation></ref><ref id="ref-26"><label>Hsu et al. (2004)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>HY</given-names></name><name><surname>Chang</surname><given-names>MH</given-names></name><name><surname>Ni</surname><given-names>YH</given-names></name><name><surname>Chen</surname><given-names>HL</given-names></name></person-group><article-title>Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan</article-title><source>Gut</source><year>2004</year><volume>53</volume><issue>10</issue><fpage>1499</fpage><lpage>1503</lpage><pub-id pub-id-type="doi">10.1136/gut.2003.034223</pub-id><pub-id pub-id-type="pmid">15361503</pub-id></element-citation></ref><ref id="ref-27"><label>Ji et al. (2011)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Si</surname><given-names>L-L</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>G-F</given-names></name><name><surname>Xin</surname><given-names>S-J</given-names></name><name><surname>Zhao</surname><given-names>J-M</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name></person-group><article-title>Variable influence of mutational patterns in reverse-transcriptase domain on replication capacity of hepatitis B virus isolates from antiviral-experienced patients</article-title><source>Clinica Chimica Acta</source><year>2011</year><volume>412</volume><issue>3&#x02013;4</issue><fpage>305</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2010.10.028</pub-id></element-citation></ref><ref id="ref-28"><label>Leong, Lin &#x00026; Nguyen (2016)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leong</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>D</given-names></name><name><surname>Nguyen</surname><given-names>MH</given-names></name></person-group><article-title>Hepatitis B surface antigen escape mutations: indications for initiation of antiviral therapy revisited</article-title><source>World Journal of Clinical Cases</source><year>2016</year><volume>4</volume><issue>3</issue><fpage>71</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.12998/wjcc.v4.i3.71</pub-id><pub-id pub-id-type="pmid">26989671</pub-id></element-citation></ref><ref id="ref-29"><label>Liang (2009)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>TJ</given-names></name></person-group><article-title>Hepatitis B: the virus and disease</article-title><source>Hepatology</source><year>2009</year><volume>49</volume><issue>S5</issue><fpage>S13</fpage><lpage>S21</lpage><pub-id pub-id-type="doi">10.1002/hep.22881</pub-id><pub-id pub-id-type="pmid">19399811</pub-id></element-citation></ref><ref id="ref-31"><label>Lin &#x00026; Kao (2015)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CL</given-names></name><name><surname>Kao</surname><given-names>JH</given-names></name></person-group><article-title>Hepatitis B virus genotypes and variants</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><year>2015</year><volume>5</volume><issue>5</issue><fpage>a021436</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a021436</pub-id><pub-id pub-id-type="pmid">25934462</pub-id></element-citation></ref><ref id="ref-32"><label>Lin et al. (2005)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>C-L</given-names></name><name><surname>Kao</surname><given-names>J-H</given-names></name><name><surname>Chen</surname><given-names>B-F</given-names></name><name><surname>Chen</surname><given-names>P-J</given-names></name><name><surname>Lai</surname><given-names>M-Y</given-names></name><name><surname>Chen</surname><given-names>D-S</given-names></name></person-group><article-title>Application of hepatitis B virus genotyping and phylogenetic analysis in intrafamilial transmission of hepatitis B virus</article-title><source>Clinical Infectious Diseases</source><year>2005</year><volume>41</volume><issue>11</issue><fpage>1576</fpage><lpage>1581</lpage><pub-id pub-id-type="doi">10.1086/497837</pub-id><pub-id pub-id-type="pmid">16267729</pub-id></element-citation></ref><ref id="ref-33"><label>Locarnini &#x00026; Yuen (2010)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locarnini</surname><given-names>SA</given-names></name><name><surname>Yuen</surname><given-names>L</given-names></name></person-group><article-title>Molecular genesis of drug-resistant and vaccine-escape HBV mutants</article-title><source>Antiviral Therapy</source><year>2010</year><volume>15</volume><issue>3 Part B</issue><fpage>451</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.3851/IMP1499</pub-id><pub-id pub-id-type="pmid">20516565</pub-id></element-citation></ref><ref id="ref-34"><label>Luber (2005)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luber</surname><given-names>AD</given-names></name></person-group><article-title>Genetic barriers to resistance and impact on clinical response</article-title><source>Journal of the International AIDS Society</source><year>2005</year><volume>7</volume><issue>1</issue><fpage>69</fpage><pub-id pub-id-type="doi">10.1186/1758-2652-7-3-69</pub-id></element-citation></ref><ref id="ref-35"><label>Luongo et al. (2015)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luongo</surname><given-names>M</given-names></name><name><surname>Critelli</surname><given-names>R</given-names></name><name><surname>Grottola</surname><given-names>A</given-names></name><name><surname>Gitto</surname><given-names>S</given-names></name><name><surname>Bernabucci</surname><given-names>V</given-names></name><name><surname>Bevini</surname><given-names>M</given-names></name><name><surname>Vecchi</surname><given-names>C</given-names></name><name><surname>Montagnani</surname><given-names>G</given-names></name><name><surname>Villa</surname><given-names>E</given-names></name></person-group><article-title>Acute hepatitis B caused by a vaccine-escape HBV strain in vaccinated subject: sequence analysis and therapeutic strategy</article-title><source>Journal of Clinical Virology</source><year>2015</year><volume>62</volume><fpage>89</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2014.11.029</pub-id><pub-id pub-id-type="pmid">25542480</pub-id></element-citation></ref><ref id="ref-36"><label>Masaadeh, Hayajneh &#x00026; Alqudah (2008)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masaadeh</surname><given-names>HA</given-names></name><name><surname>Hayajneh</surname><given-names>WA</given-names></name><name><surname>Alqudah</surname><given-names>EA</given-names></name></person-group><article-title>Hepatitis B virus genotypes and lamivudine resistance mutations in Jordan</article-title><source>World Journal of Gastroenterology</source><year>2008</year><volume>14</volume><issue>47</issue><fpage>7231</fpage><lpage>7234</lpage><pub-id pub-id-type="doi">10.3748/wjg.14.7231</pub-id><pub-id pub-id-type="pmid">19084939</pub-id></element-citation></ref><ref id="ref-37"><label>Moradi et al. (2012)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moradi</surname><given-names>A</given-names></name><name><surname>Zhand</surname><given-names>S</given-names></name><name><surname>Ghaemi</surname><given-names>A</given-names></name><name><surname>Javid</surname><given-names>N</given-names></name><name><surname>Tabarraei</surname><given-names>A</given-names></name></person-group><article-title>Mutations in the S gene region of hepatitis B virus genotype D in Golestan Province-Iran</article-title><source>Virus Genes</source><year>2012</year><volume>44</volume><issue>3</issue><fpage>382</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1007/s11262-012-0715-z</pub-id><pub-id pub-id-type="pmid">22274739</pub-id></element-citation></ref><ref id="ref-38"><label>Neumann-Fraune et al. (2014)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann-Fraune</surname><given-names>M</given-names></name><name><surname>Beggel</surname><given-names>B</given-names></name><name><surname>Kaiser</surname><given-names>R</given-names></name><name><surname>Obermeier</surname><given-names>M</given-names></name></person-group><article-title>Hepatitis B virus drug resistance tools: one sequence, two predictions</article-title><source>Intervirology</source><year>2014</year><volume>57</volume><issue>3&#x02013;4</issue><fpage>232</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1159/000361076</pub-id><pub-id pub-id-type="pmid">25034493</pub-id></element-citation></ref><ref id="ref-39"><label>Norder et al. (2004)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norder</surname><given-names>H</given-names></name><name><surname>Courouce</surname><given-names>AM</given-names></name><name><surname>Coursaget</surname><given-names>P</given-names></name><name><surname>Echevarria</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>SD</given-names></name><name><surname>Mushahwar</surname><given-names>IK</given-names></name><name><surname>Robertson</surname><given-names>BH</given-names></name><name><surname>Locarnini</surname><given-names>S</given-names></name><name><surname>Magnius</surname><given-names>LO</given-names></name></person-group><article-title>Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes</article-title><source>Intervirology</source><year>2004</year><volume>47</volume><issue>6</issue><fpage>289</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1159/000080872</pub-id><pub-id pub-id-type="pmid">15564741</pub-id></element-citation></ref><ref id="ref-40"><label>Obermeier et al. (2012)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obermeier</surname><given-names>M</given-names></name><name><surname>Pironti</surname><given-names>A</given-names></name><name><surname>Berg</surname><given-names>T</given-names></name><name><surname>Braun</surname><given-names>P</given-names></name><name><surname>Daumer</surname><given-names>M</given-names></name><name><surname>Eberle</surname><given-names>J</given-names></name><name><surname>Ehret</surname><given-names>R</given-names></name><name><surname>Kaiser</surname><given-names>R</given-names></name><name><surname>Kleinkauf</surname><given-names>N</given-names></name><name><surname>Korn</surname><given-names>K</given-names></name><name><surname>Kucherer</surname><given-names>C</given-names></name><name><surname>Muller</surname><given-names>H</given-names></name><name><surname>Noah</surname><given-names>C</given-names></name><name><surname>Sturmer</surname><given-names>M</given-names></name><name><surname>Thielen</surname><given-names>A</given-names></name><name><surname>Wolf</surname><given-names>E</given-names></name><name><surname>Walter</surname><given-names>H</given-names></name></person-group><article-title>HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge</article-title><source>Intervirology</source><year>2012</year><volume>55</volume><issue>2</issue><fpage>102</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1159/000331999</pub-id><pub-id pub-id-type="pmid">22286877</pub-id></element-citation></ref><ref id="ref-41"><label>Okamoto et al. (1988)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okamoto</surname><given-names>H</given-names></name><name><surname>Tsuda</surname><given-names>F</given-names></name><name><surname>Sakugawa</surname><given-names>H</given-names></name><name><surname>Sastrosoewignjo</surname><given-names>RI</given-names></name><name><surname>Imai</surname><given-names>M</given-names></name><name><surname>Miyakawa</surname><given-names>Y</given-names></name><name><surname>Mayumi</surname><given-names>M</given-names></name></person-group><article-title>Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes</article-title><source>Journal of General Virology</source><year>1988</year><volume>69</volume><issue>10</issue><fpage>2575</fpage><lpage>2583</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-69-10-2575</pub-id><pub-id pub-id-type="pmid">3171552</pub-id></element-citation></ref><ref id="ref-42"><label>Purdy (2007)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purdy</surname><given-names>MA</given-names></name></person-group><article-title>Hepatitis B virus S gene escape mutants</article-title><source>Asian Journal of Transfusion Science</source><year>2007</year><volume>1</volume><issue>2</issue><fpage>62</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.4103/0973-6247.33445</pub-id><pub-id pub-id-type="pmid">21938236</pub-id></element-citation></ref><ref id="ref-43"><label>Pybus &#x00026; Rambaut (2009)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pybus</surname><given-names>OG</given-names></name><name><surname>Rambaut</surname><given-names>A</given-names></name></person-group><article-title>Evolutionary analysis of the dynamics of viral infectious disease</article-title><source>Nature Reviews Genetics</source><year>2009</year><volume>10</volume><issue>8</issue><fpage>540</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/nrg2583</pub-id></element-citation></ref><ref id="ref-44"><label>Quiros-Roldan et al. (2008)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quiros-Roldan</surname><given-names>E</given-names></name><name><surname>Calabresi</surname><given-names>A</given-names></name><name><surname>Lapadula</surname><given-names>G</given-names></name><name><surname>Tirelli</surname><given-names>V</given-names></name><name><surname>Costarelli</surname><given-names>S</given-names></name><name><surname>Cologni</surname><given-names>G</given-names></name><name><surname>Zaltron</surname><given-names>S</given-names></name><name><surname>Puoti</surname><given-names>M</given-names></name><name><surname>Carosi</surname><given-names>G</given-names></name><name><surname>Torti</surname><given-names>C</given-names></name></person-group><article-title>Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV</article-title><source>Antiviral Therapy</source><year>2008</year><volume>13</volume><issue>3</issue><fpage>341</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">18572746</pub-id></element-citation></ref><ref id="ref-45"><label>Rice, Longden &#x00026; Bleasby (2000)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rice</surname><given-names>P</given-names></name><name><surname>Longden</surname><given-names>I</given-names></name><name><surname>Bleasby</surname><given-names>A</given-names></name></person-group><article-title>EMBOSS: the European molecular biology open software suite</article-title><source>Trends in Genetics</source><year>2000</year><volume>16</volume><issue>6</issue><fpage>276</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1016/s0168-9525(00)02024-2</pub-id><pub-id pub-id-type="pmid">10827456</pub-id></element-citation></ref><ref id="ref-46"><label>Sallam et al. (2017)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallam</surname><given-names>M</given-names></name><name><surname>Sahin</surname><given-names>GO</given-names></name><name><surname>Ingman</surname><given-names>M</given-names></name><name><surname>Widell</surname><given-names>A</given-names></name><name><surname>Esbjornsson</surname><given-names>J</given-names></name><name><surname>Medstrand</surname><given-names>P</given-names></name></person-group><article-title>Genetic characterization of human immunodeficiency virus type 1 transmission in the Middle East and North Africa</article-title><source>Heliyon</source><year>2017</year><volume>3</volume><issue>7</issue><elocation-id>e00352</elocation-id><pub-id pub-id-type="doi">10.1016/j.heliyon.2017.e00352</pub-id><pub-id pub-id-type="pmid">28725873</pub-id></element-citation></ref><ref id="ref-47"><label>Schaefer (2007)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaefer</surname><given-names>S</given-names></name></person-group><article-title>Hepatitis B virus taxonomy and hepatitis B virus genotypes</article-title><source>World Journal of Gastroenterology</source><year>2007</year><volume>13</volume><issue>1</issue><fpage>14</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.3748/wjg.v13.i1.14</pub-id><pub-id pub-id-type="pmid">17206751</pub-id></element-citation></ref><ref id="ref-48"><label>Shafer (2006)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shafer</surname><given-names>RW</given-names></name></person-group><article-title>Rationale and uses of a public HIV drug-resistance database</article-title><source>Journal of Infectious Diseases</source><year>2006</year><volume>194</volume><issue>s1</issue><fpage>S51</fpage><lpage>S58</lpage><pub-id pub-id-type="doi">10.1086/505356</pub-id><pub-id pub-id-type="pmid">16921473</pub-id></element-citation></ref><ref id="ref-49"><label>Sheldon &#x00026; Soriano (2008)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheldon</surname><given-names>J</given-names></name><name><surname>Soriano</surname><given-names>V</given-names></name></person-group><article-title>Hepatitis B virus escape mutants induced by antiviral therapy</article-title><source>Journal of Antimicrobial Chemotherapy</source><year>2008</year><volume>61</volume><issue>4</issue><fpage>766</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1093/jac/dkn014</pub-id><pub-id pub-id-type="pmid">18218641</pub-id></element-citation></ref><ref id="ref-50"><label>Simmonds &#x00026; Midgley (2005)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmonds</surname><given-names>P</given-names></name><name><surname>Midgley</surname><given-names>S</given-names></name></person-group><article-title>Recombination in the genesis and evolution of hepatitis B virus genotypes</article-title><source>Journal of Virology</source><year>2005</year><volume>79</volume><issue>24</issue><fpage>15467</fpage><lpage>15476</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.24.15467-15476.2005</pub-id><pub-id pub-id-type="pmid">16306618</pub-id></element-citation></ref><ref id="ref-51"><label>Stuyver et al. (2000)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuyver</surname><given-names>L</given-names></name><name><surname>De Gendt</surname><given-names>S</given-names></name><name><surname>Van Geyt</surname><given-names>C</given-names></name><name><surname>Zoulim</surname><given-names>F</given-names></name><name><surname>Fried</surname><given-names>M</given-names></name><name><surname>Schinazi</surname><given-names>RF</given-names></name><name><surname>Rossau</surname><given-names>R</given-names></name></person-group><article-title>A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness</article-title><source>Journal of General Virology</source><year>2000</year><volume>81</volume><issue>1</issue><fpage>67</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-81-1-67</pub-id><pub-id pub-id-type="pmid">10640543</pub-id></element-citation></ref><ref id="ref-52"><label>Tatematsu et al. (2009)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatematsu</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Kurbanov</surname><given-names>F</given-names></name><name><surname>Sugauchi</surname><given-names>F</given-names></name><name><surname>Mano</surname><given-names>S</given-names></name><name><surname>Maeshiro</surname><given-names>T</given-names></name><name><surname>Nakayoshi</surname><given-names>T</given-names></name><name><surname>Wakuta</surname><given-names>M</given-names></name><name><surname>Miyakawa</surname><given-names>Y</given-names></name><name><surname>Mizokami</surname><given-names>M</given-names></name></person-group><article-title>A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J</article-title><source>Journal of Virology</source><year>2009</year><volume>83</volume><issue>20</issue><fpage>10538</fpage><lpage>10547</lpage><pub-id pub-id-type="doi">10.1128/JVI.00462-09</pub-id><pub-id pub-id-type="pmid">19640977</pub-id></element-citation></ref><ref id="ref-53"><label>Teo &#x00026; Locarnini (2010)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teo</surname><given-names>CG</given-names></name><name><surname>Locarnini</surname><given-names>SA</given-names></name></person-group><article-title>Potential threat of drug-resistant and vaccine-escape HBV mutants to public health</article-title><source>Antiviral Therapy</source><year>2010</year><volume>15</volume><issue>3 Part B</issue><fpage>445</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.3851/IMP1556</pub-id><pub-id pub-id-type="pmid">20516564</pub-id></element-citation></ref><ref id="ref-54"><label>Terrault et al. (2016)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terrault</surname><given-names>NA</given-names></name><name><surname>Bzowej</surname><given-names>NH</given-names></name><name><surname>Chang</surname><given-names>KM</given-names></name><name><surname>Hwang</surname><given-names>JP</given-names></name><name><surname>Jonas</surname><given-names>MM</given-names></name><name><surname>Murad</surname><given-names>MH</given-names></name></person-group><article-title>AASLD guidelines for treatment of chronic hepatitis B</article-title><source>Hepatology</source><year>2016</year><volume>63</volume><issue>1</issue><fpage>261</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1002/hep.28156</pub-id><pub-id pub-id-type="pmid">26566064</pub-id></element-citation></ref><ref id="ref-21"><label>World Health Organization (2017)</label><element-citation publication-type="book"><person-group person-group-type="author"><collab><institution>World Health Organization</institution></collab></person-group><source>Global Hepatitis Report</source><year>2017</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name><uri xlink:href="https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/">https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/</uri></element-citation></ref><ref id="ref-55"><label>Wu et al. (2012)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Pei</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Amino acid substitutions at positions 122 and 145 of hepatitis B virus surface antigen (HBsAg) determine the antigenicity and immunogenicity of HBsAg and influence in vivo HBsAg clearance</article-title><source>Journal of Virology</source><year>2012</year><volume>86</volume><issue>8</issue><fpage>4658</fpage><lpage>4669</lpage><pub-id pub-id-type="doi">10.1128/JVI.06353-11</pub-id><pub-id pub-id-type="pmid">22301154</pub-id></element-citation></ref><ref id="ref-56"><label>Ye, Shang &#x00026; Li (2015)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Q</given-names></name><name><surname>Shang</surname><given-names>SQ</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><article-title>A new vaccine escape mutant of hepatitis B virus causes occult infection</article-title><source>Human Vaccines &#x00026; Immunotherapeutics</source><year>2015</year><volume>11</volume><issue>2</issue><fpage>407</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.4161/21645515.2014.994461</pub-id><pub-id pub-id-type="pmid">25692622</pub-id></element-citation></ref><ref id="ref-57"><label>Yu et al. (2010)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Yuan</surname><given-names>Q</given-names></name><name><surname>Ge</surname><given-names>SX</given-names></name><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Zhang</surname><given-names>YL</given-names></name><name><surname>Chen</surname><given-names>QR</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>PJ</given-names></name><name><surname>Xia</surname><given-names>NS</given-names></name></person-group><article-title>Molecular and phylogenetic analyses suggest an additional hepatitis B virus genotype &#x0201c;I&#x0201d;</article-title><source>PLOS ONE</source><year>2010</year><volume>5</volume><issue>2</issue><elocation-id>e9297</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0009297</pub-id><pub-id pub-id-type="pmid">20174575</pub-id></element-citation></ref><ref id="ref-58"><label>Zampino et al. (2002)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zampino</surname><given-names>R</given-names></name><name><surname>Lobello</surname><given-names>S</given-names></name><name><surname>Chiaramonte</surname><given-names>M</given-names></name><name><surname>Venturi-Pasini</surname><given-names>C</given-names></name><name><surname>Dumpis</surname><given-names>U</given-names></name><name><surname>Thursz</surname><given-names>M</given-names></name><name><surname>Karayiannis</surname><given-names>P</given-names></name></person-group><article-title>Intra-familial transmission of hepatitis B virus in Italy: phylogenetic sequence analysis and amino-acid variation of the core gene</article-title><source>Journal of Hepatology</source><year>2002</year><volume>36</volume><issue>2</issue><fpage>248</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/s0168-8278(01)00253-7</pub-id><pub-id pub-id-type="pmid">11830337</pub-id></element-citation></ref><ref id="ref-59"><label>Zeid, Ramadan &#x00026; Shemis (2016)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeid</surname><given-names>WMA</given-names></name><name><surname>Ramadan</surname><given-names>DI</given-names></name><name><surname>Shemis</surname><given-names>MA</given-names></name></person-group><article-title>Prevalence of mutations within major hydrophilic region of hepatitis B virus and their correlation with genotypes among chronically infected patients in Egypt</article-title><source>Arab Journal of Gastroenterology</source><year>2016</year><volume>17</volume><issue>1</issue><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.ajg.2016.03.001</pub-id><pub-id pub-id-type="pmid">27055927</pub-id></element-citation></ref><ref id="ref-60"><label>Zhang et al. (2015)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>An</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Incidence of natural resistance mutations in na&#x000ef;ve chronic hepatitis B patients: a systematic review and meta-analysis</article-title><source>Journal of Gastroenterology and Hepatology</source><year>2015</year><volume>30</volume><issue>2</issue><fpage>252</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1111/jgh.12831</pub-id><pub-id pub-id-type="pmid">25318660</pub-id></element-citation></ref><ref id="ref-61"><label>Zhou &#x00026; Holmes (2007)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Holmes</surname><given-names>EC</given-names></name></person-group><article-title>Bayesian estimates of the evolutionary rate and age of hepatitis B virus</article-title><source>Journal of Molecular Evolution</source><year>2007</year><volume>65</volume><issue>2</issue><fpage>197</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1007/s00239-007-0054-1</pub-id><pub-id pub-id-type="pmid">17684696</pub-id></element-citation></ref><ref id="ref-62"><label>Ziaee et al. (2016)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziaee</surname><given-names>M</given-names></name><name><surname>Javanmard</surname><given-names>D</given-names></name><name><surname>Sharifzadeh</surname><given-names>G</given-names></name><name><surname>Hasan Namaei</surname><given-names>M</given-names></name><name><surname>Azarkar</surname><given-names>G</given-names></name></person-group><article-title>Genotyping and mutation pattern in the overlapping MHR region of HBV isolates in Southern Khorasan, Eastern Iran</article-title><source>Hepatitis Monthly</source><year>2016</year><volume>16</volume><issue>10</issue><elocation-id>e37806</elocation-id><pub-id pub-id-type="doi">10.5812/hepatmon.37806</pub-id><pub-id pub-id-type="pmid">27882062</pub-id></element-citation></ref><ref id="ref-63"><label>Zoulim &#x00026; Locarnini (2009)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoulim</surname><given-names>F</given-names></name><name><surname>Locarnini</surname><given-names>S</given-names></name></person-group><article-title>Hepatitis B virus resistance to nucleos (t) ide analogues</article-title><source>Gastroenterology</source><year>2009</year><volume>137</volume><issue>5</issue><fpage>1593</fpage><lpage>1608.e2</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.08.063</pub-id><pub-id pub-id-type="pmid">19737565</pub-id></element-citation></ref></ref-list></back></article>